PUBLIC COMPANY
save$COGTCogent Biosciences, Inc.
$COGT37.87-0.16%Waltham, MA, USupdated 51m ago
community read0 votes
pipeline
3
marketed
1
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
1Preclinical1Marketed1pre_registration
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- —Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors
- phase1A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
- phase2(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- phase2A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
- —Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis
- phase2(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
- phase1A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
- phase3(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Insider activity
source: SEC Form 4open-market buys + sells
- Mar 31, 26SELLFairmount Funds Management LLC· −$242.62M↗
routine RSU / option mechanics (3)
- Apr 1, 26grantFerrante Karen Jean · director686 sh
- Mar 31, 26cFairmount Funds Management LLC · 7,000,000 sh
- Mar 31, 26cFairmount Funds Management LLC · 28,000 sh
🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
last refreshed 1m ago
Found something off?
comments(0)
5-min edit window · permanent after that